ALZN logo

ALZAMEND NEURO INC

ALZNNASDAQ
🏆 #4974 by market capEarnings Dec 7US Equity
$1.19▲ $0.03 (+2.59%)
Market closed · at close
🔔
Track ALZN
Get earnings, price moves & breaking news on Telegram
Track
24h▲ 2.6%
7d▼ 3.3%
14d▼ 12.5%
30d▼ 35.0%
ytd▼ 32.0%
1y▼ 52.0%
🏦Market Cap
$6M
Small Cap
📈Revenue Growth (YoY)
—
📊Gross Margin
—
💵FCF Margin
—
⚖️P/S Ratio
—
Otter Score
—
Insufficient data

Trading Snapshot

Day Range
$1.18 – $1.23
52-Week Range
$0.84 – $2.68
Volume (shares)
733
Avg Volume (shares)
—
Shares Outstanding
4.8M
Next Earnings
2026-12-07

Fundamentals Snapshot

Annual Revenue
—
Last Q Revenue
—
P/E Ratio
—
P/S Ratio
—
EPS (TTM)
$-2.27
Dividend Yield
—
Dilution (1yr)
+32.5%
ALZN logo

ALZAMEND NEURO INC

ALZN
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$0▲ +0.0% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
−$9M▲ +95.0% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
−$8M▲ +17.5% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
4.5M▲ +32.5% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$8M▲ +$3M YoY
StockOtter · stockotter.space

About ALZAMEND NEURO INC

Alzamend Neuro, Inc., a clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. Its pipeline includes AL001, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and ALZN002, which uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient's immunological system to combat Alzheimer's disease. Alzamend Neuro, Inc. was incorporated in 2016 and is headquartered in Atlanta, Georgia.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)

Insufficient data for all five components.

💧Dilution★★★★★
Overall Score
Insufficient data
—/100

Analyst Ratings

ⓘ
Consensus
Buy
7 analysts
Strong Buy2
Buy4
Hold1
Sell0
Strong Sell0
Ratings as of Oct 2026

Latest News & Updates

News unavailable.